SCHEMBL12373635

SCHEMBL12373635

CCn1c(C(C)NS(=O)(=O)c2ccc(NC(C)=O)c(Cl)c2)cnc1Oc1ccc(C)cc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 5/20 0.43
S1PR3 Q99500 1/20 0.43
ALDH1A1 P00352 2/20 0.40
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA9 Q16790 2/20 0.39
KMT2A Q03164 2/20 0.39
HTR6 P50406 1/20 0.39
ACHE P22303 2/20 0.38
CCR8 P51685 1/20 0.36
MAPT P10636 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MMP13 P45452 1/20 0.36
BCHE P06276 1/20 0.36
PDK1 Q15118 1/20 0.35
PDK2 Q15119 1/20 0.35
PDK3 Q15120 1/20 0.35
PDK4 Q16654 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2278141 0.88 S1PR1 (0.48) S1PR1S1PR3ALDH1A1KMT2A
SCHEMBL12373749 0.88 ALDH1A1 (0.44) S1PR1ALDH1A1KMT2AMAPTL3MBTL1
SCHEMBL12373481 0.87 S1PR1 (0.47) S1PR1S1PR3ALDH1A1KMT2A
SCHEMBL12373461 0.86 MAPT (0.50) ALDH1A1KMT2AMAPTL3MBTL1
SCHEMBL12373550 0.85 S1PR1 (0.59) S1PR1S1PR3ALDH1A1KMT2A
SCHEMBL12373517 0.84 S1PR1 (0.44) S1PR1S1PR3ALDH1A1CA1CA2
SCHEMBL12373473 0.83 S1PR1 (0.53) S1PR1S1PR3ALDH1A1KMT2AL3MBTL1
SCHEMBL12373648 0.83 S1PR1 (0.40) S1PR1S1PR3CA1CA2CA9
SCHEMBL12373462 0.83 ADAMTS4 (0.43) S1PR1ALDH1A1KMT2AMAPTMMP13
SCHEMBL12373690 0.82 S1PR1 (0.41) S1PR1S1PR3CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7994204-B2 Binding inhibitor of sphingosine-1-phosphate TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-08-09 US disclosed
US-7994204-B2 Binding inhibitor of sphingosine-1-phosphate TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-08-09 US disclosed
US-20090182144-A1 BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2009-07-16 US disclosed
US-20090182144-A1 BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2009-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090182144-A1 BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE S1PR1, S1PR3, S1PR2 S1PR1 1/4885S1PR3 2/4885ALDH1A1 2969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.